Table S3. Published meta-analyses on immunotherapy-induced pneumonitis.

First author, year	Studies	Patients	Cancer types	Results: all studies	Results: only NSCLC	Results: among anti-PD-1
Abdel-Rahman, 2016 (29)	11	6,671	All	AGP: OR =3.96 (95% CI, 2.02–7.79); HGP: OR =2.87 (95% CI, 0.90–9.20)	AGP: OR =3.25 (95% CI, 1.51–7.00)	NR
Costa, 2017 (30)	9	5,353	All	AGP: RR =2.28 (95% CI, 0.76–6.88)	NR	NR
Khunger, 2017 (28)	19	5,038	NSCLC	NR	NR	AGP (anti-PD-1) =3.62 (95% CI, 2.36–4.87); HGP (anti-PD-1) =1.15 (95% CI, 0.57–1.73); AGP (anti-PD-L1) =1.37 (95% CI, 0.80–1.94); HGP (anti-PD-L1) =0.41 (95% CI, 0.00–0.85)
Wu, 2017 (26)	16	6,360	All	AGP =3.29% (95% CI, 2.72–3.98); HGP =1.65% (95% CI, 1.25–2.16)	AGP =4.27% (95% CI, 3.26–5.58); HGP =2.04% (95% CI, 1.37–3.03)	AGP (anti-PD-1 vs. CTH): OR =3.90 (95% CI, 1.93–7.85); HGP (anti-PD-1 vs. CTH): OR =3.55 (95% CI, 1.29–9.76)

NSCLC, non-small cell lung cancer; AGP, all-grade pneumonitis; HGP, high-grade pneumonitis; NR, not reported.